Divergent landscapes of A-to-I editing in postmortem and living human brain
- PMID: 38926387
- PMCID: PMC11208617
- DOI: 10.1038/s41467-024-49268-z
Divergent landscapes of A-to-I editing in postmortem and living human brain
Erratum in
-
Author Correction: Divergent landscapes of A-to-I editing in postmortem and living human brain.Nat Commun. 2024 Jul 11;15(1):5828. doi: 10.1038/s41467-024-50122-5. Nat Commun. 2024. PMID: 38992062 Free PMC article. No abstract available.
Abstract
Adenosine-to-inosine (A-to-I) editing is a prevalent post-transcriptional RNA modification within the brain. Yet, most research has relied on postmortem samples, assuming it is an accurate representation of RNA biology in the living brain. We challenge this assumption by comparing A-to-I editing between postmortem and living prefrontal cortical tissues. Major differences were found, with over 70,000 A-to-I sites showing higher editing levels in postmortem tissues. Increased A-to-I editing in postmortem tissues is linked to higher ADAR and ADARB1 expression, is more pronounced in non-neuronal cells, and indicative of postmortem activation of inflammation and hypoxia. Higher A-to-I editing in living tissues marks sites that are evolutionarily preserved, synaptic, developmentally timed, and disrupted in neurological conditions. Common genetic variants were also found to differentially affect A-to-I editing levels in living versus postmortem tissues. Collectively, these discoveries offer more nuanced and accurate insights into the regulatory mechanisms of RNA editing in the human brain.
© 2024. The Author(s).
Conflict of interest statement
Girish N. Nadkarni is a founder of Renalytix, Pensieve and is a consultant to Renalytix, Heart Test Laboratories and Pensieve. He serves as a scientific advisory board member for Renalytix, Heart Test Laboratories and Pensieve. He also has equity in Renalytix, Pensieve and Verici. He has also consulted for GSK, Reata, Cambridge Capital and GLG consulting. Brian H. Kopell consults and receives consulting fees from Medtronic, Abbott, and Turing Medical. Eric Schadt has equity in, receives a salary for, and is a Corporate Executive Leader for Pathos. He is also a Board of Directors member for Sage Bionetworks and a Board of Directors member for 4YouandMe, a non-profit institute.
Figures






Update of
-
Divergent landscapes of A-to-I editing in postmortem and living human brain.medRxiv [Preprint]. 2024 May 9:2024.05.06.24306763. doi: 10.1101/2024.05.06.24306763. medRxiv. 2024. Update in: Nat Commun. 2024 Jun 26;15(1):5366. doi: 10.1038/s41467-024-49268-z. PMID: 38765961 Free PMC article. Updated. Preprint.
References
MeSH terms
Substances
Grants and funding
- 1R01AG069976-01/U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)
- R25 MH129256/MH/NIMH NIH HHS/United States
- R01 AG069976/AG/NIA NIH HHS/United States
- R03 AG080170/AG/NIA NIH HHS/United States
- 5R03AG080170-02/U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)
LinkOut - more resources
Full Text Sources